全文获取类型
收费全文 | 5668篇 |
免费 | 263篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 219篇 |
妇产科学 | 139篇 |
基础医学 | 571篇 |
口腔科学 | 61篇 |
临床医学 | 340篇 |
内科学 | 1399篇 |
皮肤病学 | 115篇 |
神经病学 | 419篇 |
特种医学 | 276篇 |
外科学 | 1093篇 |
综合类 | 155篇 |
一般理论 | 1篇 |
预防医学 | 179篇 |
眼科学 | 270篇 |
药学 | 393篇 |
中国医学 | 15篇 |
肿瘤学 | 249篇 |
出版年
2023年 | 46篇 |
2022年 | 86篇 |
2021年 | 186篇 |
2020年 | 87篇 |
2019年 | 124篇 |
2018年 | 158篇 |
2017年 | 108篇 |
2016年 | 147篇 |
2015年 | 166篇 |
2014年 | 220篇 |
2013年 | 255篇 |
2012年 | 412篇 |
2011年 | 427篇 |
2010年 | 244篇 |
2009年 | 200篇 |
2008年 | 332篇 |
2007年 | 355篇 |
2006年 | 327篇 |
2005年 | 281篇 |
2004年 | 297篇 |
2003年 | 244篇 |
2002年 | 212篇 |
2001年 | 118篇 |
2000年 | 100篇 |
1999年 | 75篇 |
1998年 | 53篇 |
1997年 | 31篇 |
1996年 | 23篇 |
1995年 | 21篇 |
1994年 | 18篇 |
1993年 | 20篇 |
1992年 | 44篇 |
1991年 | 38篇 |
1990年 | 44篇 |
1989年 | 35篇 |
1988年 | 28篇 |
1987年 | 31篇 |
1986年 | 36篇 |
1985年 | 26篇 |
1984年 | 34篇 |
1983年 | 26篇 |
1982年 | 20篇 |
1979年 | 14篇 |
1978年 | 16篇 |
1977年 | 15篇 |
1975年 | 13篇 |
1974年 | 13篇 |
1973年 | 13篇 |
1968年 | 13篇 |
1967年 | 13篇 |
排序方式: 共有5942条查询结果,搜索用时 15 毫秒
991.
992.
993.
Aakash Deep Sandeep Jain Prabodh Chander Sharma Priyanka Phogat Manav Malhotra 《Medicinal chemistry research》2012,21(8):1652-1659
A series of novel N-[5-(arylidene)-2-(aryl)-4-oxo-thiazolidin-3-yl]-4-biphenylcarboxamide derivatives was synthesized and evaluated for analgesic and anti-inflammatory activity. In this study, biphenyl-4-carboxylic acid hydrazide was converted to the corresponding aryl hydrazones using aryl aldehydes in the presence of catalytic amount of glacial acetic acid. The aryl hydrazones on reaction with thioglycolic acid in the presence of anhydrous zinc chloride yielded N-[2-(aryl)-4-oxo-thiazolidin-3-yl]-4-biphenylcarboxamide which further on reaction with aromatic aldehydes in the presence of anhydrous sodium acetate and glacial acetic acid furnished the title compounds. All compound exhibited anti-inflammatory activity at the dose 10?mg/kg. The structures of all these newly synthesized compounds were confirmed by their elemental analyses (C, H, N) and spectral data (IR and 1H NMR). 相似文献
994.
995.
Lukacs-Kornek V Malhotra D Fletcher AL Acton SE Elpek KG Tayalia P Collier AR Turley SJ 《Nature immunology》2011,12(11):1096-1104
Fibroblastic reticular cells (FRCs) and lymphatic endothelial cells (LECs) are nonhematopoietic stromal cells of lymphoid organs. They influence the migration and homeostasis of naive T cells; however, their influence on activated T cells remains undescribed. Here we report that FRCs and LECs inhibited T cell proliferation through a tightly regulated mechanism dependent on nitric oxide synthase 2 (NOS2). Expression of NOS2 and production of nitric oxide paralleled the activation of T cells and required a tripartite synergism of interferon-γ, tumor necrosis factor and direct contact with activated T cells. Notably, in vivo expression of NOS2 by FRCs and LECs regulated the size of the activated T cell pool. Our study elucidates an as-yet-unrecognized role for the lymph node stromal niche in controlling T cell responses. 相似文献
996.
997.
Stephen Pan Frederick E. Dewey Marco V. Perez Joshua W. Knowles Rong Chen Atul J. Butte Euan A. Ashley 《Current cardiovascular risk reports》2011,5(6):542-551
Cardiovascular diseases are among the leading causes of morbidity and mortality in the developed world despite advances in
cardiac care over the last few decades. Although most of these advances in cardiovascular medicine have been made through
trials of therapies on a population scale, the success of such therapies in a patient often is dependent on particular aspects
of each individual. In this review, we present the evidence for the impact that the use of personalized medicine and genetics
can have in the cardiac care of a patient, first through risk stratification based on inherent genetic risk inferred from
the results of genome-wide association studies, to the use of pharmacogenomics to guide clinical management. Finally, we discuss
the coming flood of human genome sequencing and the potential impact it will have on the care of patients from the standpoint
of cardiovascular disease. 相似文献
998.
999.
Research in the area of pharmacogenetics in psychiatry is aimed at identifying clinically relevant genetic variations that can predict treatment response. Ultimately, the goal is to individualize treatment in order to optimize outcome in disorders in which incomplete treatment response is common. Positive symptoms in patients with schizophrenia appear to be the most amenable to the currently available agents; however, negative symptoms and cognitive deficits frequently persist even when frank psychosis is well controlled. Given the relationship between these persistent traits and functional disability in schizophrenia, efforts are under way to directly target cognitive impairment and negative symptoms pharmacologically in order to improve quality of life. To date, most pharmacogenetic studies of schizophrenia have been focused on predicting clinical efficacy and side effects. In this review, we discuss the potential use of cognition as a primary outcome measure of interest in future pharmacogenetic trials of schizophrenia. 相似文献
1000.
The objective of the study is to evaluate the outcome of patients with seronegative spondyloarthritis continuing on sulphasalazine
(SSZ) and methotrexate (MTX) after a short course of infliximab. Patients with seronegative spondyloarthritis on MTX and SSZ
were given short course of infliximab therapy at 0, 2, 6 and 14 weeks. Outcome of these patients while continuing on MTX and
SSZ was assessed. Clinical features, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis
Functional Index (BASFI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were noted at baseline (pre-infliximab),
1 month, 3 months and last follow-up after last dose of infliximab infusion. Twenty-four patients were included in this study.
The mean duration of follow-up was 9.1 months. Statistically significant reduction in tender and swollen joint count was noted
at all the three visits as compared to baseline. Fall in ESR and CRP was statistically significant at 1 and 3 months, but
not at last follow-up. Mean reduction in BASDAI at 1 month ,3 month and last follow-up after last infliximab dose were 3.907
(95% CI 2.98–4.83; p < 0.001), 4.53 (95% CI 3.56–5.49; p < 0.001) and 2.48 (95% CI 1.12–3.84; p = 0.002), respectively. Mean reduction in BASFI at 1 month, 3 months and last follow-up after last infliximab dose were 4.13
(95% CI 3.23–5.04; p < 0.001), 4.34 (95% CI 2.8–5.88; p < 0.001) and 2.38 (95% CI 0.86–3.90; p = 0.005), respectively. Continuing SSZ and MTX after short course of infliximab results in sustained improvement in our patients
with seronegative spondyloarthritis in India. 相似文献